arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Definium Therapeutics, Inc.

DFTX
$40.34 ▲ +1.08 (+2.74%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
25 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Neutral
auto_awesome

Analytical Summary

Definium Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Materials sector before making investment decisions.

Market Cap $4.5B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -6.2%
FCF / Share $-0.48
Trailing P/E
Price / Book 5.9x
FCF Yield
Debt / Equity 0.04
info Valuation on last close. End-of-day price, Sep 22, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-158.99M
↓ -271.9%
FCF / Share Free cash flow per share
$-0.48
↓ -21.7%
Long-Term Debt Long-term obligations
$36.47M
↓ -10.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Financial Health
50
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 25 quarters